$7.73
2.15% yesterday
Nasdaq, Sep 08, 10:16 pm CET
ISIN
US6700021040
Symbol
NVAX

Novavax, Inc. Stock News

Neutral
Seeking Alpha
5 days ago
Novavax, Inc. (NASDAQ:NVAX ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:20 AM EDT Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Pete Stavropoulos - Cantor Presentation Pete Stavropoulos Welcome to the Cantor Global Hea...
Neutral
PRNewsWire
5 days ago
GAITHERSBURG, Md. , Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine Nuvaxovid® Intramuscular Injection 1 mL formulated to target SARS-CoV-2 Omicron LP.8.1 as an initial immunization (first and second vaccination) for those aged six years or older and a booster imm...
Neutral
PRNewsWire
13 days ago
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season GAITHERSBURG, Md. , Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026 Formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years throug...
Neutral
PRNewsWire
19 days ago
Refinancing extends maturity of most existing debt with improved terms $225 million of convertible notes due in 2031 issued, including a ~$175 million exchange for the retirement of existing convertible notes due in 2027 and ~$50 million of new money GAITHERSBURG, Md. , Aug. 21, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has entered into privately negotiated agree...
Positive
The Motley Fool
about one month ago
Novavax (NVAX) Profit Jumps on Milestone
Neutral
Seeking Alpha
about one month ago
Novavax, Inc. (NASDAQ:NVAX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & Director Luis Sanay - Corporate Participant Ruxandra Draghia-Akli - Executive VP and Head of Research & Development Silvia Taylor - Corporate Participant Conference Call Participants Alec Warren St...
Positive
Reuters
about one month ago
Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.
Neutral
PRNewsWire
about one month ago
Total revenue of $239 million in the second quarter of 2025 Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval triggered $175 million milestone payment from Sanofi Completed transition of Nuvaxovid™ commercial leadership in the U.S. to Sanofi for the 2025-2026 COVID-19 vaccination season  COVID-19- Influenza -C...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today